- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 1
The Center for Biosimilars® recaps the top news for the week of April 1, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 1.
Number 5: A new consensus report calls the nocebo effect underrecognized in the area of biosimilars and says that more research is needed on this important topic.
Number 4: Stakeholders testified before a House of Representatives subcommittee about the impact of the rising costs of insulin.
Number 3: A head-to-head study, published in The Lancet, has produced data that may help allay gastroenterologists’ concerns about using CT-P13 in Corhn disease.
Number 2: Sandoz announced that it has resubmitted its Biologics License Application for its pegfilgrastim biosimilar referencing Neulasta.
Number 1: Yet another class action lawsuit has been filed against AbbVie, maker of Humira. This time, Baltimore, Maryland, is suing both AbbVie and Amgen for delayed biosimilar competition.
Finally, last week, our e-newsletter asked whether you agree with the FDA’s decision to require 4-letter suffixes only for newly approved biologics and biosimlars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Top 5 Most-Read Policy Articles of 2024
December 28th 2024The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.
